title: Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer.
abstract: 18 patients with advanced colorectal cancer entered a phase I-II study of high-dose 48 h continuous infusion 5-fluorouracil (5-FU) for 6 weeks. 7 patients were included at the first dose level (3 g/m2) and only 1 had serious toxicity (grade 3 diarrhoea and mucositis). 7 patients were included at the second dose level (3.5 g/m2). 6 had a good tolerance to treatment, while the remaining patient had grade 4 leukopenia. 4 patients received 4 g/m2: 3 had severe toxicity (grade 4 diarrhoea, myelosuppression, mucositis, central nervous system), such that the entry of new patients was stopped. Anti-tumour activity was seen in 33% (95% confidence interval 13-59%) of the overall population. Only patients who had not had previous chemotherapy responded to treatment (response rate in this subgroup [43%, 18-71%]). The optimal dose of 5-FU was 3.5 g/m2 weekly for six cycles.
authors: Servicio de Oncología Médica, Hospital Universitario San Carlos, Ciudad Universitaria, Madrid, Spain.
authors: E
authors: E
authors: Diaz-Rubio
authors: E
authors: E
authors: Aranda
authors: M
authors: M
authors: Martin
authors: R
authors: R
authors: Gonzalez-Mancha
authors: J
authors: J
authors: Gonzalez-Larriba
authors: I
authors: I
authors: Barneto
mesh_terms: D000368:Aged; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D005472:Fluorouracil